AgeX Therapeutics Analysis
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
AgeX Therapeutics is overvalued with Real Value of 0.6 and Hype Value of 0.74. The main objective of AgeX Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what AgeX Therapeutics is worth, separate from its market price. There are two main types of AgeX Therapeutics' stock analysis: fundamental analysis and technical analysis.
The AgeX Therapeutics stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and AgeX Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
AgeX |
AgeX Stock Analysis Notes
About 76.0% of the company shares are held by company insiders. The company recorded a loss per share of 13.36. AgeX Therapeutics had not issued any dividends in recent years. The entity had 28:1000 split on the 15th of March 2024. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people. For more info on AgeX Therapeutics please contact Michael West at 510 671 8370 or go to https://www.agexinc.com.AgeX Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AgeX Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AgeX Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| AgeX Therapeutics is now traded under the symbol SER. Please update your portfolios or report it if you believe this is an error. Report It! | |
| AgeX Therapeutics is not yet fully synchronised with the market data | |
| AgeX Therapeutics has some characteristics of a very speculative penny stock | |
| AgeX Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| AgeX Therapeutics has 4.37 M in debt with debt to equity (D/E) ratio of 0.75, which is OK given its current industry classification. AgeX Therapeutics has a current ratio of 0.19, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AgeX to invest in growth at high rates of return. | |
| The entity reported the last year's revenue of 142 K. Reported Net Loss for the year was (14.8 M) with profit before taxes, overhead, and interest of 125 K. | |
| AgeX Therapeutics has about 645 K in cash with (7.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 76.0% of AgeX Therapeutics shares are held by company insiders |
AgeX Therapeutics Upcoming and Recent Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
AgeX Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 31.51 M.AgeX Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AgeX Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AgeX Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AgeX Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael West over six months ago Acquisition by Michael West of 3125 shares of AgeX Therapeutics subject to Rule 16b-3 | ||
Renondin Jeanchristophe over a year ago AgeX Therapeutics exotic insider transaction detected | ||
Juvenescence Ltd over a year ago Acquisition by Juvenescence Ltd of 756429 shares of AgeX Therapeutics subject to Rule 16b-3 | ||
Juvenescence Ltd over a year ago Bona fide gift to Juvenescence Ltd of 16447500 shares of AgeX Therapeutics subject to Section 16 | ||
Juvenescence Ltd over a year ago Acquisition by Juvenescence Ltd of 801924 shares of AgeX Therapeutics subject to Rule 16b-3 | ||
Juvenescence Ltd over a year ago Acquisition by Juvenescence Ltd of 340136 shares of AgeX Therapeutics subject to Rule 16b-3 |
AgeX Therapeutics Outstanding Bonds
AgeX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AgeX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AgeX bonds can be classified according to their maturity, which is the date when AgeX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ADVGRO 8625 30 SEP 27 Corp BondUS00840KAA79 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US00842XAA72 Corp BondUS00842XAA72 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| US00846UAL52 Corp BondUS00846UAL52 | View |
AgeX Therapeutics Predictive Daily Indicators
AgeX Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AgeX Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About AgeX Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how AgeX Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AgeX shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as AgeX Therapeutics. By using and applying AgeX Stock analysis, traders can create a robust methodology for identifying AgeX entry and exit points for their positions.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding AgeX Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |